首页> European journal of medicinal chemistry> Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.

Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Henry,Danahay

第一单位： Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, United Kingdom.

作者： Henry,Danahay ^[1] ; Martin,Gosling ^[1] ; Roy,Fox ^[2] ; Sarah,Lilley ^[2] ; Holly,Charlton ^[2] ; Jonathan D,Hargrave ^[3] ; Thomas B,Schofield ^[3] ; Duncan A,Hay ^[3] ; Naomi,Went ^[3] ; Pearl,McMahon ^[3] ; Frederic,Marlin ^[3] ; John,Scott ^[3] ; Julia,Vile ^[3] ; Steve,Hewison ^[3] ; Sarah,Ellam ^[3] ; Samantha,Brown ^[3] ; Juan,Sabater ^[4] ; Guy,Kennet ^[5] ; Sean,Lightowler ^[5] ; Stephen P,Collingwood ^[6]

作者单位： Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, United Kingdom. ^[1] Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, BN1 9RH, United Kingdom. ^[2] Evotec UK, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom. ^[3] Department of Research, Mount Sinai Medical centre, 4300 Alton Rd, Miami Beach FL 3340, USA. ^[4] Saretius, Whiteknights House (B10), University of Reading, Reading, RG6 6UR, United Kingdom. ^[5] Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, United Kingdom. Electronic address: steve@enterprisetherapeutics.com. ^[6]

关键词 Benzimidazolium Cystic fibrosis ENaC inhibitor Inhalation Low permeability Mucocilliary clearance